Arthritis, Rheumatism and Aging Medical Information System Post-Marketing Surveillance Program.
The Arthritis, Rheumatism, and Aging Post-Marketing Surveillance Program (ARAMIS-PMS) is a collection of multicenter, prospective, noninterventional, observational longitudinal studies of patients with rheumatic diseases. The ARAMIS-PMS program aims to study patients in normal clinical setting to evaluate the real-life effectiveness, toxicity, and cost effectiveness of various medications used to treat rheumatic diseases.
Singh
G
G
Department of Medicine, Stanford University School of Medicine, Palo Alto, California 94304, USA. gsingh@stanford.edu
D016907:Adverse Drug Reaction Reporting Systems / Q000458:organization & administration*; D000375:Aging; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001168:Arthritis / Q000188:drug therapy*; D002986:Clinical Trials as Topic / Q000592:standards; D006801:Humans; D007256:Information Systems / Q000458:organization & administration; D011358:Product Surveillance, Postmarketing; D015397:Program Evaluation; D014481:United States
D018501:Antirheumatic Agents